|
|
Volumn 13, Issue 7, 2002, Pages 1049-1058
|
|
Multimodal treatment with primary single-agent epirubicin in operable breast cancer: 5-year experience of the Michelangelo Cooperative Group
a
a
|
|
Author keywords
Epirubicin; Multicenter study; Multimodal therapy; Operable breast cancer; Primary chemotherapy
|
|
Indexed keywords
ANTIESTROGEN;
COBALT;
CYCLOPHOSPHAMIDE;
EPIRUBICIN;
ESTROGEN RECEPTOR;
FLUOROURACIL;
METHOTREXATE;
PROGESTERONE RECEPTOR;
TAMOXIFEN;
ADULT;
AGED;
ALOPECIA;
ARTICLE;
BREAST CANCER;
CANCER CELL;
CANCER RADIOTHERAPY;
CANCER RECURRENCE;
CANCER SURVIVAL;
CELL INVASION;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DRUG EFFICACY;
DRUG RESPONSE;
FEMALE;
FEVER;
FOLLOW UP;
HEART DISEASE;
HEMATOLOGIC DISEASE;
HUMAN;
HUMAN TISSUE;
INFECTION;
LIVER DISEASE;
LYMPH NODE METASTASIS;
MASTECTOMY;
MUCOSA INFLAMMATION;
MULTICENTER STUDY;
MULTIMODALITY CANCER THERAPY;
PARTIAL MASTECTOMY;
PRIORITY JOURNAL;
PROGNOSIS;
RANDOMIZED CONTROLLED TRIAL;
SAFETY;
SEGMENTAL MASTECTOMY;
STOMATITIS;
TREATMENT OUTCOME;
TUMOR VOLUME;
ADJUVANT CHEMOTHERAPY;
BREAST TUMOR;
CANCER STAGING;
COMPARATIVE STUDY;
CONFIDENCE INTERVAL;
DISEASE FREE SURVIVAL;
DOSE RESPONSE;
DRUG ADMINISTRATION;
ITALY;
METHODOLOGY;
MIDDLE AGED;
MORTALITY;
NEEDLE BIOPSY;
PATHOLOGY;
PROBABILITY;
PROPORTIONAL HAZARDS MODEL;
PROSPECTIVE STUDY;
SURVIVAL;
ADULT;
AGED;
BIOPSY, NEEDLE;
BREAST NEOPLASMS;
CHEMOTHERAPY, ADJUVANT;
COMPARATIVE STUDY;
CONFIDENCE INTERVALS;
DISEASE-FREE SURVIVAL;
DOSE-RESPONSE RELATIONSHIP, DRUG;
DRUG ADMINISTRATION SCHEDULE;
EPIRUBICIN;
FEMALE;
HUMAN;
ITALY;
MASTECTOMY;
MIDDLE AGE;
NEOPLASM STAGING;
PROBABILITY;
PROGNOSIS;
PROPORTIONAL HAZARDS MODELS;
PROSPECTIVE STUDIES;
SUPPORT, NON-U.S. GOV'T;
SURVIVAL ANALYSIS;
TREATMENT OUTCOME;
HUMANS;
MIDDLE AGED;
|
|
EID: 0035990833
PISSN: 09237534
EISSN: None
Source Type: Journal
DOI: 10.1093/annonc/mdf097 Document Type: Article |
|
Times cited : (9)
|
|
References (22)
|
